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Pulmonary tumour thrombotic microangiopathy (PTTM) is a rapidly progressive pulmonary disease that
is a fatal complication of malignancy. It manifests clinically as subacute respiratory failure with pul-
monary hypertension, progressive right sided heart failure, and sudden death. We describe here a case of
PTTM associated with occult metastatic signet ring cell carcinoma of the stomach. Although rare, PTTM
needs to be considered in the differential diagnosis of dyspnoea of unknown origin, particularly in pa-
tients with respiratory failure and also pulmonary hypertension, and in patients were there is no
improvement in respiratory symptoms with steroid therapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pulmonary tumour thrombotic microangiopathy (PTTM), ﬁrst
deﬁned by Von Herbay et al., in 1990, is known as a rare but fatal
pulmonary complication associated with various malignancies [1].
However, cases of tumour cells embolising to the pulmonary
vasculature have been described in the literature as early as 1930
[2]. This condition manifests as subacute respiratory failure with
pulmonary hypertension, rapidly progressive right sided heart
failure, and sudden death [3,4]. Histopathologically it is charac-
terised by diffuse intimal myoﬁbroblast proliferation in pulmonary
blood vessels, accompanied by multiple microthrombi, which
result from invasion of the pulmonary vasculature by cancer cells
[1,3]. The primary malignancy is often poorly differentiated gastric
adenocarcinoma, including signet ring cell carcinoma but it has also
been described in other upper GI malignancies as well as breast and
lung carcinoma [1,5]. The pathophysiology of this debilitating
condition remains obscure.
We describe here a case of pulmonary tumour thrombotic
microangiopathy associated with occult metastatic signet ring cell
carcinoma of the stomach.
Case report
A 41 year old male, life-long non-smoker, initially presented
with a 2 week history of worsening shortness of breath and dry
cough. Prior to admission he had been treated in the community forAnearney).
Ltd. This is an open access article ua presumed atypical pneumonia with amoxicillin and clari-
thromycin. No speciﬁc symptoms related to the gastrointestinal
system were reported at this time. No signiﬁcant past medical
history was noted. He was on no regular medication. There was a
family history of hypertrophic cardiomyopathy in his father. He
worked as a long distance lorry driver and had no occupational dust
or chemical exposure. On clinical examination he was found to be
haemodynamically stable and apyrexic with oxygen saturations of
91% on inspiring room air. Auscultation of the chest revealed
normal breath sounds with ﬁne crepitations throughout the lung
ﬁelds. No other abnormal focal examination ﬁndings were
identiﬁed.
Initial investigations: haemoglobin 158 g/L (115e165 g/L), white
blood cell count 10 109/L (4e10 109/L), platelet count 328 109
(150e450  109/L), and C reactive protein 22.3 mg/L (1e5 mg/L).
Liver and renal function tests were normal. Prothrombin time was
12.1s (9.3e11.8s), APTT was 27.2s (23.4e32.4s), Fibrinogen 4.08 g/L
(1.9e4.0 g/L) and D-dimer was 13 units (0.01e0.5 units). Arterial
blood gas demonstrated patient to have type I respiratory failure
(pO2 7.68 kPa). Chest radiograph demonstrated areas of wide-
spread scattered patchy consolidation and reticulonodular inter-
stitial changes. An initial diagnosis of interstitial or organizing
pneumonia secondary to an atypical organism was made. The pa-
tient was commenced on intravenous piperacillinwith tazobactam,
and also intravenous clarithromycin, as well as receiving oral ste-
roids, regular nebulisers, and oxygen therapy pending further
investigation.
Legionella and pneumococcal urinary antigens were negative.
HIV, CMV, ANCA, anti-GBM antibodies, and Rheumatoid Factor
were all negative. Immunoglobulins were within the normal rangender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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allergic alveolitis screenwas negative, IgG to Aspergilluswas normal
as was total IgE. Respiratory syncytial virus was positive in sputum.
Inﬂuenza viruses A and B, and Pneumocystis jiroveci, B.pertussis, and
Chlamydia psittaci PCR were negative.
A high-resolution CT scan was carried out which demonstrated
reticular nodular interstitial change with alveolar inﬁltrates and
thickening of the secondary pulmonary lobule. No obvious
lymphadenopathy or bronchovascular beading was noted. A small
pericardial effusion was noted (Fig. 1).
The patient initially improved on antibiotic and steroid therapy
however he remained hypoxic and further investigation was
undertaken.
Echocardiography demonstrated a right ventricular systolic
pressure of 75 mmHg, and the right atrium and right ventricle to be
mildly enlarged. A paradoxical motion of the ventricular septum
was noted, as well as ﬂattening of the ventricular septum in systole
consistent with right ventricular pressure overload. Overall left
ventricular function was normal (Fig. 2).
Bronchoscopy demonstrated no endobronchial mucosal abnor-
mality but thick orange jelly like secretions were observed.
Cytology demonstrated a prominent mononuclear inﬂammatory
component with numerous degenerate bronchial epithelial cells.
Occasional atypical cells with prominent nucleoli were noted,
which were thought to be reactive pneumocytes. Biopsy either
endobronchial or transbronchial was not possible due to hypoxia
worsening during the procedure. Culture of bronchial secretions
demonstrated E.coli sensitive to meropenem.
The patient improved with a change in antibiotic therapy but
subsequently deteriorated. On day 19 he developed acute unilateral
visual loss which on ophthalmological review was retinal vein
thrombosis attributed to steroid use. He became increasingly short
of breath over the next 2 days and his WCC and platelet count
began to fall precipitously. On day 24 he developed frank hae-
moptysis, type 1 respiratory failure and respiratory distress
requiring intubation and ventilation. At time of referral to ICU for
ventilatory support, he had become acutely pancytopenic with
associated coagulopathy and newly deranged LFTs. Haemoglobin
was 114 g/L(115e165 g/L), platelet count was 30 having dropped
from 328 initially on admission (150e450 109/L), white blood cell
count 3  109/L(4e10  109/L), neutrophils 35%. Prothrombin timeFig. 1. CT image showing alveolar inﬁltrwas 15.8s (9.3e11.8s), APTT was 31.7s (23.4e32.4s), and Fibrinogen
1.04 g/L (decreased from 4.8 g/L) (1.9e4.0 g/L) and D-dimer was
47.3 units (0.01e0.5units).
Repeat CT Chest, Abdomen and Pelvis at this time demonstrated
increased bilateral pulmonary inﬁltrates but no thoracic lymph-
adenopathy, or intra-thoracic or intra-abdominal mass and no ev-
idence of pulmonary embolus (Fig. 3). One small celiac axis node
was noted to be 1.5 cm. The working diagnosis remained an in-
ﬂammatory interstitial process with blood dyscrasia attributed
initially to antimicrobial therapy.
Upon transfer to ICU he was treated with IV Methylpredniso-
lone, IV Immunoglobulins, FFP and platelet transfusions. Given his
acute pancytopenia, he underwent bone marrow aspiration &
trephine biopsy, which showed a signiﬁcant inﬁltrative process
with evidence of adenocarcinomatous cells, with signet ring cells.
The patient was discussed with the acute oncologist and at the
gastrointestinal multidisciplinary meeting and given his given his
current clinical state, and with tissue diagnosis found in bone
marrow of metastatic signet ring cell carcinoma of likely gastric
origin, it was deemed inappropriate to consider any form of
chemotherapy but rather refer the patient to the palliative care
team. The patient was extubated and passed away sadly on the
same day. The patients' family declined post-mortem.
Discussion
PTTM is an uncommon complication in individuals with meta-
static cancer. It is predominantly diagnosed post-mortem and Von
Herbay found in a retrospective study examining the autopsy
ﬁndings of 630 patients with metastatic carcinoma, that PTTM was
observed in 3.3% of cases, and of these cases, 90% were associated
with gastric adenocarcinoma [1]. Antemortem diagnosis is
extremely challenging due to the rapid development of lethal
pulmonary hypertension, heart failure and death. In this case the
deﬁnitive investigation would have been a lung biopsy but his
degree of hypoxia precluded this.
PTTM should be suspected in patients with dyspnoea of un-
known origin, particularly in patients with a history of mucin-
secreting adenocarcinoma. It presents in a similar fashion to res-
piratory diseases such as pulmonary thromboembolism, pulmo-
nary hypertension, or pneumonia. Typically there is evidence ofates and reticular nodular opacities.
Fig. 2. Echocardiography demonstrating elevated right ventricular systolic pressure as estimated from the tricuspid regurgitation signal.
S. McAnearney, M. Drain / Respiratory Medicine Case Reports 16 (2015) 7e10 9metastatic disease at the time of presentation [6], but occult cancer
manifested as pulmonary thrombotic microangiopathy is more
rarely reported, as in this case.
PTTM is characterised by ﬁbrocellular intimal proliferation and
focal hypercoagulability, which together result in pulmonary artery
stenosis or obstruction, and consequently the patient develops
severe dyspnoea and pulmonary hypertension. Approximately half
of cases are complicated by disseminated intravascular coagulation
[7], as happened in this current case when the patient acutely
deteriorated requiring ventilatory support.
No treatment was administered in this current case, due to the
patients' rapid deterioration and clinical condition upon diagnosis,Fig. 3. CT showing progression of inﬁlbut if detected early enough, chemotherapy is believed to reduce
the burden of tumour cells in PTTM, and thereby lessen the stim-
ulus for intimal proliferation. Whilst no deﬁnite treatment had
been established, it is perceived chemotherapy may prolong the
survival period. Evidence also suggests serotonin antagonists may
be beneﬁcial by blocking the pathways leading to intimal ﬁbro-
cellular proliferation [5,8].
In conclusion, clinically PTTM is a rapidly progressive pulmo-
nary disease that is a fatal complication of malignancy and is
associated with a poor prognosis. It represents an important dif-
ferential diagnosis of dyspnoea of unknown origin, particularly in
patients with respiratory failure and also pulmonary hypertension.trates to conﬂuent consolidation.
S. McAnearney, M. Drain / Respiratory Medicine Case Reports 16 (2015) 7e1010In summary, it is important to suspect PTTM as a differential
diagnosis for rapidly worsening respiratory conditions particularly
if there is no improvement with steroid therapy, not only in pa-
tients with cancer, but also in patients without a cancer history, as
the early diagnosis may prolong the survival period of PTTM
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